The Goldman Sachs Group Raises Johnson & Johnson (NYSE:JNJ) Price Target to $186.00

Key Points

• Goldman Sachs raised Johnson & Johnson's price target from $185.00 to $186.00, maintaining a "buy" rating on the stock, which indicates a potential upside of 5.85% from its current price.
• Other brokerages, including JPMorgan Chase and Bank of America, have also recently adjusted their price targets for JNJ, with JPMorgan setting a target of $200.00.
• Johnson & Johnson reported earnings of $2.77 per share, exceeding analysts' estimates, and had a revenue of $23.74 billion for the last quarter.

Johnson & Johnson (NYSE:JNJ - Get Free Report) had its price objective boosted by analysts at The Goldman Sachs Group from $185.00 to $186.00 in a report issued on Friday,MarketScreener reports. The brokerage currently has a "buy" rating on the stock. The Goldman Sachs Group's target price points to a potential upside of 5.85% from the stock's current price.

A number of other brokerages have also commented on JNJ. Morgan Stanley lifted their price target on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. JPMorgan Chase & Co. upped their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a "neutral" rating in a research note on Tuesday, September 16th. Wall Street Zen raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Saturday, September 13th. Piper Sandler reiterated an "overweight" rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Finally, Bank of America upped their target price on Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and ten have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $178.80.

Johnson & Johnson Stock Performance

JNJ traded down $0.47 during trading hours on Friday, reaching $175.72. The company's stock had a trading volume of 520,108 shares, compared to its average volume of 8,911,765. The firm has a market cap of $423.19 billion, a PE ratio of 18.78, a price-to-earnings-growth ratio of 2.24 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $181.16. The company's 50-day moving average is $172.80 and its 200-day moving average is $161.64.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company's revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the company posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 0.16% of the stock is currently owned by corporate insiders.

Institutional Trading of Johnson & Johnson

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Evolution Wealth Management Inc. acquired a new position in shares of Johnson & Johnson during the 2nd quarter worth approximately $27,000. Semmax Financial Advisors Inc. increased its holdings in shares of Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company's stock valued at $31,000 after acquiring an additional 72 shares during the last quarter. GFG Capital LLC bought a new position in Johnson & Johnson in the second quarter worth about $35,000. Highline Wealth Partners LLC increased its holdings in shares of Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after acquiring an additional 86 shares during the period. Finally, Stone House Investment Management LLC acquired a new position in shares of Johnson & Johnson during the first quarter valued at $47,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.